Bradley Martin
Concepts (326)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Analgesics, Opioid | 40 | 2024 | 575 | 8.560 |
Why?
| Chronic Pain | 17 | 2024 | 182 | 5.960 |
Why?
| Opioid-Related Disorders | 17 | 2024 | 393 | 4.180 |
Why?
| Drug Overdose | 9 | 2024 | 159 | 3.190 |
Why?
| Medicaid | 22 | 2021 | 252 | 2.740 |
Why?
| Drug Prescriptions | 14 | 2024 | 97 | 2.690 |
Why?
| Tramadol | 3 | 2024 | 30 | 2.450 |
Why?
| Alcoholism | 4 | 2022 | 235 | 2.440 |
Why?
| Antipsychotic Agents | 9 | 2018 | 233 | 1.700 |
Why?
| Retrospective Studies | 37 | 2025 | 6263 | 1.690 |
Why?
| Adult | 55 | 2025 | 13577 | 1.670 |
Why?
| Middle Aged | 53 | 2025 | 12611 | 1.580 |
Why?
| United States | 47 | 2024 | 4955 | 1.570 |
Why?
| Osteoarthritis, Knee | 3 | 2017 | 96 | 1.520 |
Why?
| Anticoagulants | 6 | 2025 | 256 | 1.450 |
Why?
| Humans | 94 | 2025 | 50503 | 1.450 |
Why?
| Pain | 10 | 2018 | 387 | 1.440 |
Why?
| Health Care Costs | 9 | 2016 | 167 | 1.350 |
Why?
| Viscosupplements | 3 | 2017 | 14 | 1.260 |
Why?
| Hyaluronic Acid | 3 | 2017 | 34 | 1.240 |
Why?
| Female | 64 | 2025 | 27081 | 1.230 |
Why?
| Young Adult | 26 | 2025 | 4102 | 1.220 |
Why?
| Medication Adherence | 6 | 2016 | 129 | 1.220 |
Why?
| Adolescent | 35 | 2024 | 6443 | 1.210 |
Why?
| Mental Disorders | 7 | 2025 | 415 | 1.210 |
Why?
| Aged | 38 | 2025 | 9741 | 1.200 |
Why?
| Male | 61 | 2025 | 25907 | 1.190 |
Why?
| Emergency Service, Hospital | 6 | 2016 | 484 | 1.170 |
Why?
| Schizophrenia | 5 | 2009 | 258 | 1.110 |
Why?
| Cross-Over Studies | 2 | 2025 | 228 | 1.110 |
Why?
| Arthroplasty, Replacement, Knee | 4 | 2017 | 285 | 1.070 |
Why?
| Substance-Related Disorders | 5 | 2021 | 611 | 1.030 |
Why?
| Venous Thromboembolism | 2 | 2025 | 74 | 1.010 |
Why?
| Patient Compliance | 6 | 2009 | 233 | 1.010 |
Why?
| Veterans | 10 | 2024 | 574 | 0.960 |
Why?
| Atrial Fibrillation | 3 | 2016 | 188 | 0.940 |
Why?
| Psychotropic Drugs | 1 | 2025 | 76 | 0.920 |
Why?
| Cohort Studies | 13 | 2024 | 1452 | 0.920 |
Why?
| Psychotherapy | 1 | 2025 | 110 | 0.890 |
Why?
| Suicide | 1 | 2025 | 83 | 0.870 |
Why?
| Asthma | 3 | 2015 | 284 | 0.870 |
Why?
| Cost-Benefit Analysis | 5 | 2020 | 266 | 0.850 |
Why?
| Insurance, Health | 7 | 2020 | 128 | 0.820 |
Why?
| Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 172 | 0.780 |
Why?
| Neck Pain | 2 | 2021 | 10 | 0.770 |
Why?
| Back Pain | 2 | 2021 | 38 | 0.760 |
Why?
| Arkansas | 14 | 2024 | 1985 | 0.750 |
Why?
| Drug Utilization | 11 | 2017 | 76 | 0.750 |
Why?
| Central Nervous System Stimulants | 1 | 2023 | 209 | 0.740 |
Why?
| Arthralgia | 1 | 2021 | 45 | 0.740 |
Why?
| Acetaminophen | 3 | 2015 | 276 | 0.730 |
Why?
| Hospitalization | 5 | 2016 | 675 | 0.720 |
Why?
| Professional-Patient Relations | 1 | 2021 | 48 | 0.720 |
Why?
| Analgesics, Non-Narcotic | 2 | 2012 | 117 | 0.710 |
Why?
| Narcotic Antagonists | 2 | 2024 | 136 | 0.680 |
Why?
| Logistic Models | 8 | 2016 | 900 | 0.680 |
Why?
| Naloxone | 1 | 2020 | 81 | 0.650 |
Why?
| Hydrocodone | 3 | 2024 | 20 | 0.640 |
Why?
| Oxycodone | 3 | 2024 | 27 | 0.640 |
Why?
| Warfarin | 3 | 2016 | 83 | 0.630 |
Why?
| Insurance, Pharmaceutical Services | 1 | 2019 | 24 | 0.630 |
Why?
| Legislation, Drug | 1 | 2019 | 18 | 0.630 |
Why?
| Contraception | 1 | 2019 | 29 | 0.620 |
Why?
| Decision Support Techniques | 2 | 2016 | 70 | 0.620 |
Why?
| Risk Factors | 12 | 2025 | 3724 | 0.610 |
Why?
| Adrenal Cortex Hormones | 2 | 2017 | 99 | 0.590 |
Why?
| Buprenorphine | 3 | 2024 | 145 | 0.570 |
Why?
| Guidelines as Topic | 1 | 2018 | 109 | 0.570 |
Why?
| Mammography | 1 | 2018 | 101 | 0.570 |
Why?
| Practice Guidelines as Topic | 3 | 2017 | 468 | 0.560 |
Why?
| Follow-Up Studies | 7 | 2024 | 2242 | 0.550 |
Why?
| Histamine H2 Antagonists | 1 | 2016 | 26 | 0.550 |
Why?
| Peptic Ulcer | 1 | 2016 | 14 | 0.540 |
Why?
| Purinergic P2Y Receptor Antagonists | 3 | 2022 | 29 | 0.520 |
Why?
| Proton Pump Inhibitors | 1 | 2016 | 83 | 0.520 |
Why?
| Education, Pharmacy, Graduate | 1 | 2016 | 19 | 0.520 |
Why?
| Pyridones | 1 | 2016 | 34 | 0.510 |
Why?
| Risk | 4 | 2020 | 324 | 0.500 |
Why?
| Inappropriate Prescribing | 1 | 2016 | 22 | 0.500 |
Why?
| Safety-Based Drug Withdrawals | 1 | 2015 | 7 | 0.500 |
Why?
| Dextropropoxyphene | 1 | 2015 | 6 | 0.500 |
Why?
| Prescription Drugs | 5 | 2014 | 37 | 0.500 |
Why?
| For-Profit Insurance Plans | 1 | 2015 | 2 | 0.490 |
Why?
| Brain Ischemia | 2 | 2016 | 164 | 0.490 |
Why?
| Pyrazoles | 1 | 2016 | 111 | 0.480 |
Why?
| Mass Screening | 1 | 2018 | 344 | 0.480 |
Why?
| Quinolines | 1 | 2015 | 41 | 0.470 |
Why?
| Acetates | 1 | 2015 | 49 | 0.470 |
Why?
| Stress, Psychological | 1 | 2016 | 266 | 0.470 |
Why?
| Anticonvulsants | 2 | 2006 | 123 | 0.470 |
Why?
| Opiate Substitution Treatment | 3 | 2024 | 99 | 0.470 |
Why?
| Diabetic Neuropathies | 1 | 2015 | 57 | 0.460 |
Why?
| Insurance Claim Reporting | 2 | 2011 | 11 | 0.460 |
Why?
| Time Factors | 8 | 2018 | 2935 | 0.450 |
Why?
| Critical Illness | 1 | 2016 | 302 | 0.450 |
Why?
| Insurance Claim Review | 4 | 2010 | 36 | 0.450 |
Why?
| Curriculum | 2 | 2018 | 400 | 0.450 |
Why?
| Palliative Care | 1 | 2016 | 190 | 0.440 |
Why?
| Pain Management | 1 | 2015 | 180 | 0.440 |
Why?
| Stroke | 2 | 2016 | 495 | 0.430 |
Why?
| Neoplasms | 1 | 2023 | 1251 | 0.420 |
Why?
| Breast Neoplasms | 2 | 2023 | 1201 | 0.420 |
Why?
| Injections, Intra-Articular | 3 | 2017 | 36 | 0.420 |
Why?
| Computers, Handheld | 1 | 2013 | 25 | 0.420 |
Why?
| Prescription Drug Misuse | 3 | 2024 | 34 | 0.420 |
Why?
| Health Expenditures | 2 | 2004 | 69 | 0.410 |
Why?
| United States Department of Veterans Affairs | 5 | 2024 | 291 | 0.400 |
Why?
| Benzodiazepines | 3 | 2024 | 70 | 0.390 |
Why?
| Health Personnel | 2 | 2016 | 247 | 0.370 |
Why?
| Community Pharmacy Services | 3 | 2020 | 66 | 0.360 |
Why?
| Databases, Factual | 7 | 2022 | 673 | 0.350 |
Why?
| Kidney Failure, Chronic | 2 | 2022 | 201 | 0.340 |
Why?
| Cross-Sectional Studies | 5 | 2022 | 1610 | 0.320 |
Why?
| Age Factors | 5 | 2018 | 1110 | 0.320 |
Why?
| Motor Vehicles | 1 | 2009 | 15 | 0.320 |
Why?
| Antidepressive Agents | 2 | 2009 | 177 | 0.320 |
Why?
| Automobile Driving | 1 | 2009 | 22 | 0.310 |
Why?
| Medication Errors | 1 | 2009 | 25 | 0.310 |
Why?
| Pharmacists | 3 | 2019 | 145 | 0.310 |
Why?
| Case-Control Studies | 5 | 2023 | 1156 | 0.310 |
Why?
| Cost of Illness | 3 | 2013 | 114 | 0.300 |
Why?
| Physicians, Primary Care | 2 | 2018 | 46 | 0.300 |
Why?
| Quality-Adjusted Life Years | 2 | 2020 | 63 | 0.300 |
Why?
| Health Resources | 2 | 2012 | 74 | 0.290 |
Why?
| Pain Measurement | 6 | 2021 | 270 | 0.290 |
Why?
| College Admission Test | 2 | 2018 | 13 | 0.280 |
Why?
| Antimanic Agents | 1 | 2007 | 14 | 0.280 |
Why?
| School Admission Criteria | 2 | 2018 | 35 | 0.280 |
Why?
| Hypoglycemic Agents | 1 | 2008 | 173 | 0.280 |
Why?
| Schools, Pharmacy | 2 | 2018 | 53 | 0.270 |
Why?
| Pharmaceutical Services | 2 | 2018 | 52 | 0.270 |
Why?
| Constipation | 1 | 2006 | 34 | 0.270 |
Why?
| Orthopedic Procedures | 2 | 2017 | 70 | 0.270 |
Why?
| Propensity Score | 2 | 2017 | 136 | 0.270 |
Why?
| Postoperative Complications | 2 | 2025 | 1033 | 0.270 |
Why?
| Overweight | 1 | 2009 | 215 | 0.270 |
Why?
| Medicare | 4 | 2023 | 247 | 0.260 |
Why?
| Georgia | 5 | 2006 | 41 | 0.260 |
Why?
| Knee Joint | 2 | 2017 | 164 | 0.260 |
Why?
| Students, Pharmacy | 2 | 2018 | 124 | 0.250 |
Why?
| Odds Ratio | 4 | 2020 | 551 | 0.250 |
Why?
| Multivariate Analysis | 3 | 2017 | 583 | 0.240 |
Why?
| Controlled Substances | 1 | 2024 | 6 | 0.240 |
Why?
| Risperidone | 2 | 2010 | 25 | 0.240 |
Why?
| Colectomy | 1 | 2025 | 37 | 0.240 |
Why?
| Polypharmacy | 1 | 2004 | 15 | 0.240 |
Why?
| Aged, 80 and over | 8 | 2023 | 3226 | 0.230 |
Why?
| Drug Costs | 2 | 2020 | 38 | 0.230 |
Why?
| Renal Dialysis | 2 | 2022 | 171 | 0.220 |
Why?
| Haloperidol | 1 | 2003 | 47 | 0.210 |
Why?
| North Carolina | 4 | 2009 | 52 | 0.210 |
Why?
| Hemorrhage | 2 | 2023 | 197 | 0.210 |
Why?
| Direct Service Costs | 1 | 2003 | 5 | 0.210 |
Why?
| Irritable Bowel Syndrome | 1 | 2003 | 17 | 0.210 |
Why?
| Employment | 1 | 2003 | 90 | 0.210 |
Why?
| Aftercare | 1 | 2023 | 72 | 0.210 |
Why?
| Prevalence | 4 | 2018 | 971 | 0.200 |
Why?
| Premedication | 1 | 2002 | 17 | 0.200 |
Why?
| Age Distribution | 4 | 2018 | 170 | 0.200 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2008 | 519 | 0.200 |
Why?
| Health Services Needs and Demand | 1 | 2004 | 156 | 0.200 |
Why?
| Child | 8 | 2019 | 6906 | 0.200 |
Why?
| Neuralgia | 1 | 2023 | 66 | 0.200 |
Why?
| Common Cold | 1 | 2002 | 5 | 0.200 |
Why?
| Bronchitis | 1 | 2002 | 11 | 0.200 |
Why?
| Thromboembolism | 1 | 2002 | 55 | 0.190 |
Why?
| Accidents | 1 | 2021 | 20 | 0.190 |
Why?
| Colorectal Neoplasms | 1 | 2025 | 260 | 0.190 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 154 | 0.190 |
Why?
| Depressive Disorder, Major | 2 | 2020 | 151 | 0.190 |
Why?
| Forecasting | 3 | 2009 | 147 | 0.180 |
Why?
| Ambulatory Care Facilities | 1 | 2002 | 120 | 0.180 |
Why?
| Mental Health Services | 1 | 2004 | 202 | 0.180 |
Why?
| Respiratory Tract Infections | 1 | 2002 | 78 | 0.180 |
Why?
| Interprofessional Relations | 2 | 2018 | 83 | 0.180 |
Why?
| Patient Discharge | 1 | 2023 | 321 | 0.180 |
Why?
| Afghan Campaign 2001- | 2 | 2018 | 40 | 0.180 |
Why?
| Administration, Oral | 2 | 2016 | 434 | 0.180 |
Why?
| Obesity | 1 | 2009 | 1121 | 0.170 |
Why?
| Proportional Hazards Models | 3 | 2017 | 415 | 0.170 |
Why?
| Administration, Intranasal | 1 | 2020 | 30 | 0.170 |
Why?
| Markov Chains | 1 | 2020 | 30 | 0.170 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2021 | 174 | 0.170 |
Why?
| Brain Neoplasms | 1 | 2023 | 291 | 0.170 |
Why?
| Social Media | 1 | 2022 | 99 | 0.170 |
Why?
| Preventive Health Services | 1 | 2020 | 49 | 0.160 |
Why?
| Delivery of Health Care | 1 | 2021 | 303 | 0.160 |
Why?
| Sepsis | 1 | 2021 | 225 | 0.160 |
Why?
| Drug Administration Schedule | 3 | 2011 | 370 | 0.160 |
Why?
| Guideline Adherence | 3 | 2025 | 136 | 0.160 |
Why?
| Insurance Coverage | 1 | 2020 | 110 | 0.150 |
Why?
| Health Care Surveys | 2 | 2011 | 175 | 0.150 |
Why?
| Public Health Surveillance | 1 | 2018 | 13 | 0.150 |
Why?
| Thiazoles | 2 | 2016 | 53 | 0.150 |
Why?
| Sleep Deprivation | 1 | 2018 | 17 | 0.150 |
Why?
| Papillomavirus Vaccines | 1 | 2019 | 67 | 0.150 |
Why?
| Pharmacies | 1 | 2019 | 60 | 0.150 |
Why?
| Advisory Committees | 1 | 2018 | 65 | 0.150 |
Why?
| Physicians | 1 | 2021 | 232 | 0.150 |
Why?
| Metabolic Diseases | 1 | 2018 | 44 | 0.140 |
Why?
| Lung Neoplasms | 1 | 2023 | 601 | 0.140 |
Why?
| Veterans Health | 2 | 2014 | 62 | 0.140 |
Why?
| Least-Squares Analysis | 2 | 2009 | 40 | 0.140 |
Why?
| Molecular Weight | 1 | 2017 | 82 | 0.140 |
Why?
| Acute Pain | 1 | 2017 | 11 | 0.140 |
Why?
| Papillomavirus Infections | 1 | 2019 | 168 | 0.140 |
Why?
| Treatment Outcome | 7 | 2010 | 5283 | 0.140 |
Why?
| Educational Measurement | 1 | 2018 | 206 | 0.140 |
Why?
| Monte Carlo Method | 1 | 2016 | 85 | 0.130 |
Why?
| Early Detection of Cancer | 1 | 2018 | 163 | 0.130 |
Why?
| Dose-Response Relationship, Drug | 4 | 2014 | 1372 | 0.130 |
Why?
| Anti-Bacterial Agents | 1 | 2002 | 745 | 0.130 |
Why?
| Education, Pharmacy | 1 | 2018 | 146 | 0.130 |
Why?
| Chronic Disease | 4 | 2010 | 573 | 0.130 |
Why?
| Health Services Accessibility | 1 | 2020 | 424 | 0.120 |
Why?
| Geriatrics | 1 | 2016 | 45 | 0.120 |
Why?
| Models, Theoretical | 1 | 2016 | 170 | 0.120 |
Why?
| Sulfides | 1 | 2015 | 28 | 0.120 |
Why?
| Cyclopropanes | 1 | 2015 | 24 | 0.120 |
Why?
| Pyridines | 1 | 2016 | 131 | 0.120 |
Why?
| Renal Insufficiency, Chronic | 1 | 2018 | 174 | 0.120 |
Why?
| Thrombosis | 1 | 2018 | 250 | 0.120 |
Why?
| Anti-Asthmatic Agents | 1 | 2015 | 29 | 0.120 |
Why?
| Societies, Medical | 1 | 2016 | 187 | 0.120 |
Why?
| Severity of Illness Index | 2 | 2016 | 978 | 0.120 |
Why?
| Self Report | 1 | 2016 | 206 | 0.120 |
Why?
| Long-Term Care | 3 | 2012 | 50 | 0.110 |
Why?
| Health Literacy | 1 | 2016 | 129 | 0.110 |
Why?
| Enoxaparin | 2 | 2025 | 31 | 0.110 |
Why?
| California | 2 | 2004 | 86 | 0.110 |
Why?
| Comorbidity | 5 | 2017 | 623 | 0.110 |
Why?
| Child, Preschool | 4 | 2011 | 3942 | 0.110 |
Why?
| Prescriptions | 2 | 2011 | 10 | 0.100 |
Why?
| Risk Assessment | 2 | 2015 | 1270 | 0.100 |
Why?
| Monitoring, Physiologic | 1 | 2013 | 118 | 0.100 |
Why?
| Sensitivity and Specificity | 1 | 2015 | 859 | 0.100 |
Why?
| Cardiovascular Diseases | 1 | 2018 | 461 | 0.100 |
Why?
| Managed Care Programs | 1 | 2012 | 36 | 0.100 |
Why?
| Hypertension, Pulmonary | 1 | 2012 | 124 | 0.090 |
Why?
| Body Mass Index | 2 | 2013 | 677 | 0.080 |
Why?
| Calibration | 1 | 2009 | 57 | 0.080 |
Why?
| International Classification of Diseases | 1 | 2009 | 63 | 0.080 |
Why?
| United States Food and Drug Administration | 2 | 2010 | 90 | 0.080 |
Why?
| Clozapine | 2 | 2010 | 26 | 0.080 |
Why?
| Reference Values | 1 | 2009 | 307 | 0.080 |
Why?
| Analysis of Variance | 1 | 2010 | 552 | 0.080 |
Why?
| Treatment Refusal | 1 | 2009 | 35 | 0.080 |
Why?
| Evidence-Based Medicine | 1 | 2010 | 253 | 0.080 |
Why?
| Carbamazepine | 1 | 2007 | 13 | 0.070 |
Why?
| Lithium Compounds | 1 | 2007 | 11 | 0.070 |
Why?
| Mental Health | 1 | 2010 | 228 | 0.070 |
Why?
| Alendronate | 1 | 2007 | 23 | 0.070 |
Why?
| Valproic Acid | 1 | 2007 | 31 | 0.070 |
Why?
| Fractures, Spontaneous | 1 | 2007 | 14 | 0.070 |
Why?
| Chemotherapy, Adjuvant | 1 | 2007 | 121 | 0.070 |
Why?
| Osteoporosis, Postmenopausal | 1 | 2007 | 30 | 0.070 |
Why?
| Affect | 1 | 2007 | 103 | 0.070 |
Why?
| Drug Labeling | 1 | 2006 | 11 | 0.070 |
Why?
| Bone Density Conservation Agents | 1 | 2007 | 74 | 0.070 |
Why?
| Predictive Value of Tests | 1 | 2008 | 930 | 0.060 |
Why?
| Adrenergic beta-Agonists | 1 | 2005 | 43 | 0.060 |
Why?
| Self Disclosure | 1 | 2005 | 13 | 0.060 |
Why?
| Depression | 1 | 2009 | 582 | 0.060 |
Why?
| Eligibility Determination | 1 | 2004 | 19 | 0.060 |
Why?
| Factor Analysis, Statistical | 1 | 2004 | 78 | 0.060 |
Why?
| Urban Population | 1 | 2005 | 151 | 0.060 |
Why?
| Health Surveys | 2 | 2018 | 239 | 0.060 |
Why?
| Prescription Fees | 1 | 2004 | 14 | 0.060 |
Why?
| Length of Stay | 1 | 2007 | 629 | 0.050 |
Why?
| Algorithms | 1 | 2007 | 625 | 0.050 |
Why?
| Drug Therapy, Combination | 1 | 2004 | 384 | 0.050 |
Why?
| Laparoscopy | 1 | 2025 | 173 | 0.050 |
Why?
| MEDLINE | 1 | 2002 | 7 | 0.050 |
Why?
| Prospective Studies | 1 | 2008 | 2378 | 0.050 |
Why?
| Neuropsychological Tests | 1 | 2003 | 355 | 0.050 |
Why?
| Cognition Disorders | 1 | 2003 | 213 | 0.050 |
Why?
| Gastrointestinal Hemorrhage | 1 | 2022 | 80 | 0.050 |
Why?
| Infant | 2 | 2010 | 3628 | 0.050 |
Why?
| Regression Analysis | 2 | 2013 | 382 | 0.050 |
Why?
| Longitudinal Studies | 2 | 2014 | 735 | 0.040 |
Why?
| Data Collection | 1 | 2002 | 280 | 0.040 |
Why?
| Patient Protection and Affordable Care Act | 1 | 2020 | 51 | 0.040 |
Why?
| Needs Assessment | 1 | 2020 | 136 | 0.040 |
Why?
| Quality of Health Care | 1 | 2020 | 184 | 0.040 |
Why?
| Incidence | 2 | 2014 | 1032 | 0.040 |
Why?
| Pharmacy | 1 | 2018 | 54 | 0.040 |
Why?
| Pharmacoepidemiology | 1 | 2017 | 8 | 0.040 |
Why?
| Drug Interactions | 1 | 2018 | 206 | 0.040 |
Why?
| Universities | 1 | 2018 | 171 | 0.040 |
Why?
| Vaccination | 1 | 2019 | 280 | 0.030 |
Why?
| Pilot Projects | 1 | 2019 | 698 | 0.030 |
Why?
| Communication | 1 | 2018 | 250 | 0.030 |
Why?
| Electronic Health Records | 1 | 2018 | 220 | 0.030 |
Why?
| Reminder Systems | 1 | 2016 | 27 | 0.030 |
Why?
| Qualitative Research | 1 | 2018 | 349 | 0.030 |
Why?
| Decision Making | 1 | 2018 | 272 | 0.030 |
Why?
| Medication Therapy Management | 1 | 2016 | 23 | 0.030 |
Why?
| Attitude of Health Personnel | 1 | 2018 | 352 | 0.030 |
Why?
| Ischemic Attack, Transient | 1 | 2013 | 55 | 0.030 |
Why?
| Survival Analysis | 1 | 2014 | 661 | 0.030 |
Why?
| Lipids | 1 | 2013 | 152 | 0.030 |
Why?
| Linear Models | 1 | 2013 | 279 | 0.020 |
Why?
| Diagnosis, Dual (Psychiatry) | 1 | 2012 | 41 | 0.020 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2017 | 383 | 0.020 |
Why?
| Diagnostic Tests, Routine | 1 | 2012 | 28 | 0.020 |
Why?
| Blood Pressure | 1 | 2013 | 531 | 0.020 |
Why?
| Blood Glucose | 1 | 2013 | 446 | 0.020 |
Why?
| Adolescent Behavior | 1 | 2011 | 103 | 0.020 |
Why?
| Dibenzothiazepines | 1 | 2010 | 10 | 0.020 |
Why?
| Hypnotics and Sedatives | 1 | 2010 | 74 | 0.020 |
Why?
| Diabetes Mellitus | 1 | 2013 | 279 | 0.020 |
Why?
| Off-Label Use | 1 | 2010 | 26 | 0.020 |
Why?
| Quinolones | 1 | 2010 | 41 | 0.020 |
Why?
| Mood Disorders | 1 | 2009 | 58 | 0.020 |
Why?
| Anxiety Disorders | 1 | 2009 | 123 | 0.020 |
Why?
| Piperazines | 1 | 2010 | 119 | 0.020 |
Why?
| Headache | 1 | 2008 | 75 | 0.020 |
Why?
| Sex Factors | 1 | 2009 | 712 | 0.020 |
Why?
| Confidence Intervals | 1 | 2007 | 154 | 0.020 |
Why?
| Probability | 1 | 2007 | 164 | 0.020 |
Why?
| Drug Utilization Review | 1 | 2005 | 23 | 0.020 |
Why?
| Drug Monitoring | 1 | 2005 | 79 | 0.010 |
Why?
| Bone Density | 1 | 2007 | 386 | 0.010 |
Why?
| Registries | 1 | 2007 | 563 | 0.010 |
Why?
| Quality of Life | 1 | 2008 | 851 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2005 | 1197 | 0.010 |
Why?
|
|
Martin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|